Holen Sie sich die Stockscreener-App
2.16
1.41%
0.03
Handel nachbörslich:
2.16
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price - simplywall.st
Elutia Inc. (NASDAQ:ELUT) Shares Purchased by Millennium Management LLC - Defense World
Citadel Advisors LLC Acquires Shares of 22,431 Elutia Inc. (NASDAQ:ELUT) - Defense World
Brokers Issue Forecasts for Elutia FY2026 Earnings - Defense World
Elutia (NASDAQ:ELUT) Shares Down 1% – Time to Sell? - Defense World
Aziyo Biologics Holds Annual Stockholders Meeting - TipRanks
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET By Investing.com - Investing.com South Africa
CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET - Investing.com
Elutia v. Medtronic: Delaware court rules on indemnity and insurance obligations in FiberCel lawsuit - Insurance Business America
ELUT stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
ELUT stock touches 52-week low at $1.61 amid market challenges - Investing.com India
Elutia Inc. Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method - marketscreener.com
Elutia announces publication of article on measuring antibiotic release - TipRanks
Elutia (ELUT) Innovates with New Antibiotic Release Method | ELUT Stock News - GuruFocus
Revolutionary Drug Testing Method Cuts Medical Device Development Time from 14 Days to Just 30 Hours - Stock Titan
FY2025 EPS Estimates for Elutia Lifted by Cantor Fitzgerald - Defense World
Lake Street Capital Has Lowered Expectations for Elutia (NASDAQ:ELUT) Stock Price - Defense World
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock N - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Sto - GuruFocus
Elutia (ELUT) Stock: Lake Street Adjusts Price Target | ELUT Stock News - GuruFocus
Elutia (ELUT) Price Target Reduced by Lake Street | ELUT Stock News - GuruFocus
Elutia Q1 2025 slides: EluPro sales surge 84% amid overall revenue decline - Investing.com Nigeria
Elutia Inc (ELUT) Q1 2025 Earnings Call Highlights: Strategic Growth and Challenges in Transition - Yahoo Finance
Elutia Inc. Reports Strong Growth in EluPro Sales - TipRanks
Earnings call transcript: Elutia Q1 2025 beats EPS forecast, stock rises - Investing.com
SEC Form 424B5 filed by Elutia Inc. - Quantisnow
Elutia Inc Reports Q1 2025 Earnings: EPS of -$0.21 Meets Estimates, Revenue of $3.1 Million Misses Estimates - GuruFocus
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - The Manila Times
Elutia Inc (ELUT) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Renaissance Technologies LLC Sells 11,700 Shares of Elutia Inc. (NASDAQ:ELUT) - Defense World
Elutia Inc. Ends Distribution Agreement with LeMaitre - TipRanks
Elutia Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Aziyo Biologics (ELUT) Receives a New Rating from Lake Street - The Globe and Mail
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | ELUT Stock News - GuruFocus
Elutia (ELUT) Resumes Direct Control Over Cardiovascular Portfol - GuruFocus
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - The Manila Times
Elutia Ends LeMaitre Partnership: Strategic Shift Promises 80% Margins in $2.9M Cardiovascular Line - Stock Titan
Elutia Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 - The Manila Times
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29 | ELUT Stock News - GuruFocus
Elutia's Top Scientist Reveals Drug Development Strategy: Key Regulatory Catalysts in Focus - Stock Titan
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29 - TradingView
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Ou - GuruFocus
Elutia to Participate in Chardan's Trending Issues in Drug Devel - GuruFocus
Elutia (ELUT) Begins EluPro Clinical Study to Enhance Patient Outcomes | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | ELUT Stock News - GuruFocus
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice - The Manila Times
Elutia Inc. Initiates Clinical Study for EluPro™ to Enhance Cardiac Device Outcomes - Nasdaq
Elutia Begins Landmark Registry Study for Revolutionary CIED Protection Technology EluPro - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Elutia (ELUT) Reports Resilience Amid Global Tariff Changes | EL - GuruFocus
Elutia Confirms No Material Impact from Global Tariffs | ELUT St - GuruFocus
Elutia unaffected by global tariffs, maintains US focus By Investing.com - Investing.com South Africa
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):